Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Paradym CRT 8770 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PhD | NO_INTERVENTION | - |
| Name | Type | Description |
|---|---|---|
| Paradym CRT 8770 | DEVICE | - |
Inclusion Criteria: * Patient eligible for implantation of a CRT-D device according to current available guidelines for cardiac resynchronization therapy * Severe HF (NYHA Class III or IV) at the time of enrollment * At least one HF-related event (as defined for primary objective) within the last 6...
Top 20 of 31 competitors
Paradym CRT 8770 is a cardiac resynchronization therapy device used for heart failure. It is currently in Phase 3 clinical development and is being studied in patients with heart failure. The device is designed to deliver cardiac resynchronization therapy to improve heart function in affected individuals.
Paradym CRT 8770 is developed by LivaNova PLC, a company publicly traded under the ticker LIVN. LivaNova is responsible for the clinical development and commercialization of this cardiac resynchronization therapy device for heart failure.
Paradym CRT 8770 is in Phase 3 clinical development. It is an investigational device and has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the device is being evaluated for use in patients with heart failure.
Paradym CRT 8770 has one completed Phase 3 clinical trial, identified as NCT02167789. This trial, titled 'Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT Device,' enrolled 520 participants with heart failure across multiple countries including the United States, Canada, and several European nations.
Paradym CRT 8770 is not FDA approved. It is an investigational device currently in Phase 3 clinical development. The completed Phase 3 trial (NCT02167789) evaluated the device in 520 patients with heart failure, but regulatory approval has not been granted.